This graphic provides a closer look at PrEP uptake at several sites in South Africa along with lessons learned. It appears in AVAC Report 2017: Mixed messages and how to untangle them.
Oral PrEP Uptake in South Africa: A snapshot from mid-2017
Oral PrEP Uptake in the United States
This is a graph of PrEP uptake in the United States mapped with major PrEP milestones. It appears in AVAC Report 2017: Mixed messages and how to untangle them.
Prevention Paradigm, 2017-beyond
While several different interventions exist for contraception, there aren’t yet a full array of options for HIV prevention. Choices matter. This graphic appears in AVAC Report 2017: Mixed messages and how to untangle them.
The South Africa PrEP Story: What “starting out” looks like
This graphic charts how many people in South Africa tested as HIV negative each month vs. how many people commenced oral PrEP from month-to-month. It appears in AVAC Report 2017: Mixed messages and how to untangle them.
Target Tracking, 2010–2020
Calculating progress toward the UNAIDS Fast Track Goals is complex but ambitious targets are the best kind. AVAC has long argued they propel action even if they aren’t met. But when it comes to achieving epidemic control, progress must be properly calculated, and can never be confused with success. This graphic appears in AVAC Report 2017: Mixed messages and how to untangle them.
Timeline for DAIDS HIV Trials Network Recompetition
This graphic looks ahead from 2017 through 2027 at the DAIDS HIV Trials Network Recompetition process. It appears in AVAC Report 2017: Mixed messages and how to untangle them.
The UNAIDS 10-Point Plan for Making Progress on Prevention
The UNAIDS 10-point plan for making progress on prevention omits elements of the “research-to-rollout” continuum, and leaves the definition of prevention out—focusing on the “how” rather than the “what”. This graphic appears in AVAC Report 2017: Mixed messages and how to untangle them.
US Public Sector Investment in HIV Prevention R&D, Compared to All Other Funding, 2012–2016
This graphic tracks US public sector investment in HIV prevention research & development vs all other funding sources over the four year period of 2012-2016. For much more on HIV prevention research & development funding, visit www.hivresourcetracking.org.
Driving Product Introduction and Access
AVAC has always advocated for closing critical prevention gaps. Now we’re taking our mission further. With African and global partners, we’re stepping beyond advocacy to generate the knowledge and tools that countries need to more quickly deliver new advances.
We’re engaging directly with national decision-makers to identify and overcome delivery hurdles for PrEP. We’re examining the preferences and experiences of people at high risk for HIV, so that future tools—long-acting injectables, vaginal rings and others—can be optimized to meet their needs.
Investment in HIV Prevention Research & Development
Because money matters as much as messages, this Px Wire centerspread summarizes current investments, and trends over time, in HIV-prevention research and development. This full-color feature is excerpted from the recently-released report on HIV prevention research and development investment produced by AVAC and partners in the field.